ProfileGDS5678 / 1435463_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 73% 68% 67% 71% 64% 56% 64% 66% 76% 81% 73% 76% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1727768
GSM967853U87-EV human glioblastoma xenograft - Control 24.7260473
GSM967854U87-EV human glioblastoma xenograft - Control 34.1524868
GSM967855U87-EV human glioblastoma xenograft - Control 44.1329467
GSM967856U87-EV human glioblastoma xenograft - Control 54.4760171
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8729364
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4940356
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8661264
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.9861266
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.1177476
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8178381
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.7019573
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.0254976
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1286368